Nanospect (Human Serum Albumin)

Human serum albumin increases plasma oncotic pressure, which draws water from the interstitial space into the bloodstream. This osmotic shift expands circulating blood volume, improves tissue perfusion, and supports hemodynamic stability while also serving as a carrier for various endogenous and exogenous substances.

The dose of Nanospect is individualized and determined by the prescribing clinician based on the patient’s clinical condition, albumin level, and fluid requirements. Dosage calculations consider factors such as body weight, severity of hypoalbuminemia, and the volume of fluid loss.

Human serum albumin is classified as a Category C product for pregnancy, meaning it should only be used if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding, so clinicians should weigh the benefits against possible risks before administration.

To order Nanospect, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Nanospect (human serum albumin) is a natural protein‑based colloid, offering oncotic pressure similar to native plasma. Compared with synthetic colloids such as hydroxyethyl starch, albumin has a lower risk of coagulopathy and renal impairment, but it is generally more expensive and requires cold‑chain storage.

Nanospect must be stored at 2‑8 °C, protected from light, and kept in its original container. It should not be frozen or shaken vigorously. Before use, inspect the solution for particulate matter or discoloration and allow it to reach room temperature if required for infusion.

Nanospect is administered intravenously, typically as an infusion. The rate and volume are determined by the prescriber, who may start with a slow infusion to assess tolerance and then adjust based on the patient’s response and clinical goals.

Serious risks include anaphylactic reactions, severe fluid overload leading to pulmonary edema, and rare transmission of infectious agents. Patients with known albumin hypersensitivity, severe cardiac or renal dysfunction, or uncontrolled hypertension require close monitoring during administration.

Nanospect should be avoided in individuals with a documented allergy to human serum albumin, in patients with uncontrolled congestive heart failure or severe renal impairment where fluid overload is a concern, and in those receiving incompatible intravenous solutions without proper assessment.